CN102758006B - Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene - Google Patents
Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene Download PDFInfo
- Publication number
- CN102758006B CN102758006B CN201210126663.9A CN201210126663A CN102758006B CN 102758006 B CN102758006 B CN 102758006B CN 201210126663 A CN201210126663 A CN 201210126663A CN 102758006 B CN102758006 B CN 102758006B
- Authority
- CN
- China
- Prior art keywords
- abl
- probe
- gene
- kit
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit for detecting a relative expression of a leukemia BCR/ABL (b3a2, b2a2) fusion gene. The kit comprises erythrocyte lysing solution, TRIzol, chloroform, absolute ethyl alcohol, ReverTraAceqPCRRTKit, a detection system PRC solution, a positive reference substance and a negative reference substance. The kit is characterized in that the detection system PCR solution comprises THUNDERBIRDqPCRMIX, upstream and downstream primers for detecting a target gene are b3a2-F, b2a2-F, b3a2/b2a2-R and a b3a2/b2a2-probe, and primers for detecting a reference gene Abl are abl-F, abl-R and an abl-probe.
Description
Technical field
The invention belongs to life science and biological technical field, a kind of gene detecting kit particularly, adopt probe for real-time fluorescence quantitative PCR technique, can be to BCR/ABL (b3a2 in acute myeloblastic leukemia (AML) patient body of mankind's chronic myelocytic leukemia (CML), acute lymphoblastic leukemia (ALL) and minority, b2a2) fusion gene expression level detects, can effectively save detection time, improve accuracy of detection.
Background technology
Leukemia is the abnormal clone's property malignant disease of a class hemopoietic stem cell.Leukemia cell in its clone loses the ability of further differentiation and maturation and is stuck in cytocerastic different steps.In marrow and other hemopoietic tissues, a large amount of hyperplasia of leukemia cell are gathered and infiltrate other Organ and tissues, make normal hematopoiesis suppressed simultaneously, clinical manifestation be anaemia, hemorrhage, infect and each organ infiltrates symptom.According to leukemia cell's maturity and natural history, leukemia can be divided into acute and chronic two large classes.Acute leukemia disease progression is rapid, and natural history only has several weeks to the several months.Generally can be divided into acute myeloid leukemia (AML) and the large class of acute lymphoblastic leukemia (ALL) two according to leukemia cell's series ownership.And chronic leukemia is due to the cell hyperplasia of differentiation and maturation that has function, so chronic leukemia is a kind of because signal conduction is bad or uncontrolled cellular proliferation institute illness extremely, but not dysmaturity extremely.Chronic leukemia is common chronic myelocytic leukemia (CML), lymphocytic leukemia (CLL).Because type of leukemia is different, treatment plan and prognosis are also not quite similar, and therefore diagnose after establishment, further somatotype.About the cause and onset of disease mechanism of human leukemia, completely not clear yet so far.The known cause of disease has infective agent, ionizing rays, chemical substance, inherited genetic factors and immunologic dysfunction etc.Think that at present the leukemia cause of disease is the interactional result of above various factors.
It is long-armed that mankind abl gene is positioned at No. 9 karyomit(e)s, has 1b, 1a and 2～11 totally 12 exons.Transcribe and start from 1b or 1a, two kinds of mRNA length of formation are respectively 7kb and 6kb, and two kinds of synthetic protein molecular weights are all about 145, and the former is positioned cytolemma, and the latter is mainly in nucleus.It is long-armed that bcr gene is positioned at No. 22 karyomit(e)s, has 23 exons.Protein product molecular weight is 160.1st～63 amino acid of bcr albumen are Dimerized structures, participate in the polymeric formation of bcr albumen.Bcr albumen participates in Cycle Regulation, but detailed process is also very not clear and definite.Bcr gene break point concentrates on three regions: main (major bcr, M-bcr), less important (minor bcr, m-bcr) and μ (μ-bcr) region.Abl gene break is positioned at the 1st or intron 2.Because breaking point differs, bcr/abl fusion gene and mRNA thereof and protein product are diversity.The bcr gene break point of chronic myelocytic leukemia is often positioned at M-bcr, is mainly b2a2 and b3a2, and molecular weight of albumen is 210kb.
In actual applications, for detection of BCR/ABL (b3a2, b2a2) method of fusion gene expression level is mainly fluorescence in situ hybridization, although this method is comparatively directly perceived, process of the test is too loaded down with trivial details, and the reagent type needing is various, waste time and energy, and test-results needs veteran expert to carry out interpretation, and result interpretation exists larger subjectivity, thereby limited to a certain extent the application of this method.
Real-time fluorescence quantitative PCR method has higher sensitivity and specificity, and can detect in real time PCR, can accurately reflect the expression of BCR/ABL (b3a2, b2a2) in patient body, save a large amount of detection times, also avoided the generation of residual contamination.Common method has SYBR GreenI dye method, two probe hybridization methods and Taqman technology etc.Wherein SYBR GreenI is owing to being non-saturable dye, and specificity, not as two probe hybridization methods and Taqman method, must judge its specificity by observing solubility curve; And two probe method hybrid method cost is comparatively expensive.Therefore this research adopts real-time fluorescence PCR technology in conjunction with Taqman probe method, to be applied to the gene test of BCR/ABL (b3a2, b2a2).
Summary of the invention
In view of detecting BCR/ABL (b3a2 in prior art, b2a2) deficiency, the present invention has designed detection internal reference/primer, probe sequence for goal gene, with fluorescent quantitative PCR technique, detects leukemia BCR/ABL (b3a2, b2a2) fusion gene relative expression quantity.By adjusting primer concentration and probe concentration and the ratio of two genes, the reaction system of optimize PCR and reaction conditions, developed a kind of test kit for detection of leukemia BCR/ABL fusion gene relative expression quantity.
For detection of leukemia BCR/ABL (b3a2, b2a2) test kit of fusion gene relative expression quantity, comprise erythrocyte cracked liquid, TRIzol, chloroform, dehydrated alcohol, ReverTraAce qPCRRT Kit, detection system PCR reaction solution, positive reference substance and negative control product, it is characterized in that:
Detection system PCR reaction solution comprises that THUNDERBIRD qPCR MIX, testing goal gene use downstream primer b3a2-F, b2a2-F, b3a2/b2a2-R, probe b3a2/b2a2-Probe, detect reference gene Abl primer abl-F, abl-R, probe abl-Probe; Wherein,
b3a2-F：GATTTAAGCAGAGTTCA
b2a2-F：TGTGTGAAACTCCAGACTGT
b3a2/b2a2-R：TCCTTGGAGTTCCAACGA
b3a2/b2a2-Probe：FAM-AGCCCTTCAGCGGCCAGTAGCATCT-TAMRA
abl-F：GCCGTGAAGACCTTGAAGGAG
abl-R：ATGATATAGAACGGGGGCTC
abl-Probe：FAM-ACCTGGTGCAGCTCCTTGGG-TAMRA。
Described positive reference substance is respectively the solution that contains b3a2, b2a2 gene; Described negative control product are the solution without b3a2 and b2a2 gene.
The qPCR cDNA reagent kit product that ReverTraAce qPCRRT KitWei TOYOBO company wherein produces.
The quantitative PCR reagent that THUNDERBIRD qPCR MIXWei TOYOBO company produces, product specification is QPS-101.
Use test kit of the present invention, by real-time fluorescence PCR technology in conjunction with adopting Tapman probe, can be to BCR/ABL (b3a2, b2a2) expression level of fusion gene detects, and accuracy of detection is high, and simple to operate, can reduce testing cost, save detection time.Adopt two calibration curve methods, by building BCR/ABL (b3a2, b2a2) and the standard quantitative curve of reference gene abl, the reference gene copy number of accurate quantification sample and BCR/ABL (b3a2, b2a2) copy number, than ImmunohistochemistryMethods Methods in the past and Δ CT method now, it is high that this test kit has precision, and result is convenient to the advantages such as interpretation.In addition this test kit carries out rational proportion and optimization by required primer, the probe of reaction system, makes experiment condition reach best, thereby saved loaded down with trivial details condition, gropes link, has greatly promoted conventional efficient.This test kit after tested specificity is good, highly sensitive, easy and simple to handle.Can be used for auxiliary early diagnosis, early prevention and the high risk population's of the acute myeloblastic leukemia (AML) of chronic myelocytic leukemia (CML), acute lymphoblastic leukemia (ALL) and minority screening clinically.
Accompanying drawing explanation
Fig. 1: b2a2 positive findings schematic diagram.
Fig. 2: b2a2 negative findings schematic diagram.
Fig. 3: b3a2 positive findings schematic diagram.
Fig. 4: b3a2 negative findings schematic diagram.
Embodiment
Test kit for detection of leukemia BCR/ABL (b3a2, b2a2) fusion gene relative expression quantity of the present invention, comprising:
Erythrocyte cracked liquid;
TRIzol；
Chloroform;
Dehydrated alcohol;
ReverTra Ace qPCR RT Kit (TOYOBO company);
Detection system PCR reaction solution: THUNDERBIRD Probe qPCR Mix (2 *), b3a2/b2a2 upstream and downstream each 0.8uM of primer, b3a2/b2a2-probe (probe) 0.4uM; Abl upstream and downstream each 0.8uM of primer, abl-probe (probe) 0.4uM; Wherein:
b3a2-F：GATTTAAGCAGAGTTCA；
b2a2-F：TGTGTGAAACTCCAGACTGT；
b3a2/b2a2-R：TCCTTGGAGTTCCAACGA；
b3a2/b2a2-Probe：FAM-AGCCCTTCAGCGGCCAGTAGCATCT-TAMRA；
abl-F：GCCG TGAAGACC TTGAAGGAG；
abl-R：ATGATATAGAACGGGGGCTC；
abl-Probe：FAM-ACCTGGTGCAGCTCCTTGGG-TAMRA
Positive reference substance: respectively containing BCR/ABL (b3a2, b2a2) genome solution;
Negative control product: not containing BCR/ABL (b3a2, b2a2) genome solution.
The using method of test kit of the present invention:
(1) in extracting blood, organize RNA: in the centrifuge tube of clean 1.5ml, add 1ml erythrocyte cracked liquid, get anticoagulation 0.5ml and mix.The standing 10min of room temperature; The centrifugal 5min of 5000rpm, abandons supernatant, collects the cell of bottom; Again add 0.5ml erythrocyte cracked liquid, the centrifugal 5min of 5000rpm, abandons supernatant, collects the cell of bottom; In cell, add 1ml TRIzol, piping and druming is until precipitate dissolving completely, the static 5min of room temperature repeatedly; Add 0.2ml chloroform, concussion evenly; 4 ℃ of centrifugal 10min of 14000rpm, draw supernatant layer and are transferred in another new centrifuge tube; Add isopyknic Virahol, fully mix up and down, the standing 10min of room temperature; 4 ℃ of centrifugal 10min of 14000rpm, abandon supernatant, add 75% ethanol 1ml, and washing tube wall gently turns upside down; 4 ℃ of centrifugal 5min of 14000rpm, abandon ethanol; Drying at room temperature 10-15min, adds 20ulRNase-free water dissolution precipitation.
(2) with reference to the Rever Tra Ace qPCR RT Kit test kit specification sheets of TOYOBO company, RNA is reversed to cDNA.
(3) reagent configuration: by detecting each X ul of people's umber configuration detection system PCR reaction solution, every person-portion 23ul packing:
X=23ul reaction solution * (part negative control+1, part positive control+1,8 parts of internal references (typical curve)+8 part goal gene (typical curve)+n part sample+1 part blank);
(4) application of sample: add 2ulcDNA in detection system PCR reaction solution; Positive control and negative control directly add 2ul positive reference substance and negative control product; Blank adds 2ul physiological saline or does not add any material.
(5) detect: detect and carry out on real-time fluorescence PCR instrument, available instrument comprises ABI7300,7500 (U.S. Applied Biosystems companies) etc.Reaction conditions: 95 ℃ of denaturation 1min; 95 ℃ of 15s, 40 circulations of 58 ℃ of 35sec, fluorescent signal gathers when 58 ℃ of 35sec.
(6) result judgement: threshold line is adjusted to background signal and negative amplification more than line, and system calculates copy number automatically according to typical curve and CT value.
1), when internal reference is positive, it is effective that detected result is just thought;
2) positive judging criterion:, Ct < 36, positive; 35≤Ct≤38, are the doubtful positive, need to again verify; Ct > 38, negative.
Adopt kit for detecting nucleic acid of the present invention to detect clinical samples
Fetch and deliver acute myeloblastic leukemia (AML) patient anticoagulation sample 20 examples of chronic myelocytic leukemia (CML), acute lymphoblastic leukemia (ALL) and the minority of inspection, by method described in embodiment 2, extract geneome RNA, reagent preparation and detect.
Every part of sample adds 2ul in detection system PCR reaction solution.Do the positive, feminine gender, blank, each portion of the typical curve of reference gene/goal gene simultaneously.The fluorescent PCR instrument in 96 holes can detect 38 duplicate samples simultaneously, and each sample repeats for 2 times, a positive control, a negative control and a blank.Be only 100 minutes detection time.
Experimental result is compared with special reporting the result of laboratory of inspection, determines the accuracy rate of sample detection.Some positive result is as following table:
Table 1 is the contrast of this experimental result and PCR Lab result.As can be seen from the above table, have 45 examples to conform to the detected result of PCR in 46 routine samples, coincidence rate reaches 97.8%.Illustrating that detection kit of the present invention and spy examine utilizes conventional fluorescent quantitation method to compare, and not only detected result accuracy is high, and has shortened detection time, has improved detection efficiency.
Get 4 parts of clinical samples to be checked, by method described in embodiment 2, extract genome, reagent preparation and detect.
Every duplicate samples adds 2ul in detection system PCR reaction solution.Do the positive, feminine gender, each portion of blank simultaneously.With fluorescent PCR instrument, detect, the time is 100 minutes.
As shown in Figure 1, the amplified signal of reference gene abl shows that tested sample genome extracts successfully to the detected result figure of sample 1, and detected result is effective, before the b2a2CT value < 36 of sample 1, has amplified signal, so sample 1 is the b2a2 positive.
As shown in Figure 2, the amplified signal of reference gene abl shows that tested sample genome extracts successfully to the detected result figure of sample 2, and detected result is effective, and the b2a2CT value > 38 of sample 2 is afterwards without amplified signal, so sample 2 is b2a2 feminine gender.
As shown in Figure 3, the amplified signal of reference gene abl shows that tested sample genome extracts successfully to the detected result figure of sample 3, and detected result is effective, before the b3a2CT value < 36 of sample 3, has amplified signal, so sample 3 is the b3a2 positive.
As shown in Figure 4, the amplified signal of reference gene abl shows that tested sample genome extracts successfully to the detected result figure of sample 4, and detected result is effective, and the b3a2CT value > 38 of sample 4 is afterwards without amplified signal, so sample 4 is b3a2 feminine gender.
SEQUENCE LISTING
<110> Wuhan company limited of Ai Dikang medical test institute
<120> is for detection of the test kit of leukemia BCR/ABL (b3a2, b2a2) fusion gene relative expression quantity
<130>
<160> 7
<170> PatentIn version 3.3
<210> 1
<211> 17
<212> DNA
<213> artificial sequence
<400> 1
<210> 2
<211> 20
<212> DNA
<213> artificial sequence
<400> 2
<210> 3
<211> 18
<212> DNA
<213> artificial sequence
<400> 3
<210> 4
<211> 25
<212> DNA
<213> artificial sequence
<400> 4
agcccttcag cggccagtag catct 25
<210> 5
<211> 21
<212> DNA
<213> artificial sequence
<400> 5
<210> 6
<211> 20
<212> DNA
<213> artificial sequence
<400> 6
<210> 7
<211> 20
<212> DNA
<213> artificial sequence
<400> 7
Claims (2)
1. for detection of leukemia BCR/ABL b3a2, the test kit of b2a2 fusion gene relative expression quantity, comprise erythrocyte cracked liquid, TRIzol, chloroform, dehydrated alcohol, ReverTra Ace qPCR RT Kit, detection system PCR reaction solution, positive reference substance and negative control product, it is characterized in that:
Detection system PCR reaction solution comprises that THUNDERBIRD qPCR MIX, testing goal gene use downstream primer b3a2-F, b2a2-F, b3a2/ b2a2-R, probe b3a2/b2a2-Probe, detecting reference gene Abl primer is abl-F, abl-R, probe abl-Probe; Wherein,
b3a2-F: GATTTAAGCAGAGTTCA
b2a2-F: TGTGTGAAACTCCAGACTGT
b3a2/b2a2-R: TCCTTGGAGTTCCAACGA
b3a2/b2a2-Probe: FAM-AGCCCTTCAGCGGCCAGTAGCATCT-TAMRA
abl-F: GCCGTGAAGACCTTGAAGGAG
abl-R: ATGATATAGAACGGGGGCTC
abl-Probe: FAM-ACCTGGTGCAGCTCCTTGGG-TAMRA。
2. test kit as claimed in claim 1, is characterized in that described positive reference substance is respectively the solution that contains b3a2, b2a2 gene; Described negative control product are the solution without b3a2 and b2a2 gene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210126663.9A CN102758006B (en) | 2012-04-25 | 2012-04-25 | Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210126663.9A CN102758006B (en) | 2012-04-25 | 2012-04-25 | Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310588945.5A Division CN103667457B (en) | 2012-04-25 | 2012-04-25 | The primer of detection leukemia BCR/ABL b3a2, b2a2 fusion gene relative expression quantity and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102758006A CN102758006A (en) | 2012-10-31 |
| CN102758006B true CN102758006B (en) | 2014-03-12 |
Family
ID=47052658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210126663.9A Active CN102758006B (en) | 2012-04-25 | 2012-04-25 | Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102758006B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102965433A (en) * | 2012-09-29 | 2013-03-13 | 李艳 | Kit for detecting mRNA expression quantity of M BCR fusion gene |
| CN103571945B (en) * | 2013-09-27 | 2015-05-06 | 沈阳艾迪康医学检验所有限公司 | Method, primer, probe and kit for screening and identifying BCR-ABL unusual fusion types |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081001A2 (en) * | 2009-01-09 | 2010-07-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
| CN101838682A (en) * | 2009-03-20 | 2010-09-22 | 江苏迈迪基因生物科技有限公司 | Leukemia fusion gene combined parallel detecting method and diagnostic reagent kit |
-
2012
- 2012-04-25 CN CN201210126663.9A patent/CN102758006B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081001A2 (en) * | 2009-01-09 | 2010-07-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
| CN101838682A (en) * | 2009-03-20 | 2010-09-22 | 江苏迈迪基因生物科技有限公司 | Leukemia fusion gene combined parallel detecting method and diagnostic reagent kit |
Non-Patent Citations (4)
| Title |
|---|
| Josefina Serrano等.Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection.《BLOOD》.2000,第95卷(第8期),2659-2665. |
| Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection;Josefina Serrano等;《BLOOD》;20000415;第95卷(第8期);2659-2665 * |
| 实时定量RT-PCR监测慢性粒细胞白血病患者造血干细胞移植后bcr-abl+mRNA水平;秦亚溱等;《中华血液杂志》;20060831;第27卷(第8期);511-514 * |
| 秦亚溱等.实时定量RT-PCR监测慢性粒细胞白血病患者造血干细胞移植后bcr-abl+mRNA水平.《中华血液杂志》.2006,第27卷(第8期),511-514. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102758006A (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2195450T4 (en) | Methods of using miRNA FOR DETECTION IN VIVO cell death | |
| CN102676663B (en) | Nucleic acid detection kit for detecting BRCA1mRNA | |
| CN102649977B (en) | Kit for detecting relative expression index of leukemia BCR/ABL (m-bcr) fusion gene | |
| KR20140064732A (en) | A method of diagnosing neoplasms | |
| CN109055538B (en) | Exosome miRNA marker and kit for rheumatoid arthritis | |
| CN108018379A (en) | A kind of prawn irido virus real-time fluorescence quantitative PCR detection kit | |
| CN102399898A (en) | Single nucleotide polymorphism (SNP) marker related with clinically cryptogenic non-obstructive azoospermia aided diagnosis and application of SNP marker | |
| CN107699617A (en) | One kind early diagnosis septicopyemia triggers acute injury of kidney molecular marked compound miR 452, kit and application | |
| CN102758006B (en) | Kit for detecting relative expression of leukemia BCR/ABL (b3a2, b2a2) fusion gene | |
| CN105925703A (en) | Method for screening miRNA markers in renal cancer peripheral blood and renal cancer diagnosis marker miR-210 | |
| CN103667457A (en) | Primer and method for detecting leukemia BCR/ABL b3a2 and b2a2 fusion gene relative transcript level | |
| CN102732618B (en) | Kit used for detecting relative expression of AML1-ETO fusion gene | |
| CN106906288A (en) | Detect the primer and method of leukaemia CDX2 gene expression doses | |
| CN107574246A (en) | Detect TBLR1 RAR α and PRKAR1A RAR alpha fusion gene relative expression quantity primed probe methods | |
| CN103667453A (en) | Method, primers and probe for detecting relative expression quantity of 11q23/MLL fusion genes | |
| CN107385038A (en) | Detect oligonucleotides, method and the kit of ZNF198 FGFR1 fusions in sample | |
| CN102776282B (en) | Kit for detecting relevant expression quantity of AML-EVI1 (acute myelocytic leukemia-ecotropic virus integration site 1) fusion gene | |
| US10590463B2 (en) | Diagnostic methods and kits for monitoring response to chemotherapy in ovarian cancer | |
| CN104561373B (en) | Kit for detecting goldfish haematopoietic necrosis virus and application thereof | |
| CN103789415A (en) | Method for detecting mutation on locus deltaF508 of CFTR (Cystic Fibrosis Transmembrane Regulator) gene and oligonucleotide | |
| CN107287325A (en) | Detect oligonucleotides, method and the kit of BCR FGFR1 fusions | |
| CN109207585A (en) | Immune thrombocytopenia lncRNA marker and kit and application | |
| CN107151699A (en) | Detect the kit and method of NUP214 ABL1 gene relative expression quantities | |
| CN103757102A (en) | Method and oligonucleotide for detecting type-B TEL-ABL fusion gene | |
| CN103555827B (en) | Primers, method, and kit used for detecting BCR/ABL fusion gene ABL kinase domain drug resistance mutation sites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |